HealthMore in Health→
Summit Therapeutics Drops After Apparent Phase 3 Miss Revives the Market’s Biotech Patience Problem
Key Takeaways
- Summit Therapeutics shares fell nearly 20% after the close on May 1, 2026.
- The trigger was described as an apparent statistical miss in part of a Phase 3 trial for ivonescimab.
- The move reflects how sharply biotech investors now react to ambiguous late-stage data.
DE
DT Editorial Team··via endpoints.news